Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model.

Laboratory investigation; a journal of technical methods and pathology - 1 Jan 2016

Parhar Ranjit S, Zou Minjing, Al-Mohanna Futwan A, Baitei Essa Y, Assiri Abdullah M, Meyer Brian F, Shi Yufei

Abstract excerpt

Papillary thyroid carcinoma (PTC) accounts for >80% thyroid malignancies, and BRAF(V600E) mutation is frequently found in >40% PTC. Interleukin-12 (IL-12) is a proinflammatory heterodimeric cytokine with strong antitumor activity. It is not known whether IL-12 immunotherapy is effective against Braf(V600E)-induced PTC. In the present study, we investigated the effectiveness of IL-12 immunotherapy against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Interleukin-12

Share to Macrophages

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Transforming Growth Factor beta

Source

Identifiers

PMID: 26501867
DOI: 10.1038/labinvest.2015.126

Genes

TPO
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model.PMID 26501867Read ↗

BRAF <sup>V600E</sup> expression in thyrocytes causes recruitment of immunosuppressive STABILIN-1 macrophagesSemantic proximity Read ↗

PD-1 Blockade Delays Tumor Growth by Inhibiting an Intrinsic SHP2/Ras/MAPK Signalling in Thyroid Cancer CellsSemantic proximity Read ↗

Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse Model.Semantic proximity Read ↗

IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.Semantic proximity Read ↗

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.Semantic proximity Read ↗

Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.Semantic proximity Read ↗

BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer.Semantic proximity Read ↗

Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.Semantic proximity Read ↗

Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors.Semantic proximity Read ↗

Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model.Semantic proximity Read ↗

Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.Semantic proximity Read ↗

Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.